Director Paul A. Ainsworth was quoted in the article “Latest Humira Dispute Highlights Biosimilar Trade Secrets Dangers,” published by IAM. From the article:

“It is also crucial for all biosimilar businesses to take steps to avoid falling foul of trade secrets protections, comments Sterne Kessler’s Paul Ainsworth: ‘Companies that hire people who previously worked on a product that they want to bring to market need to take extra steps to ensure that they are not creating a problem, even if they have no intention of misappropriating secrets.’ Businesses should be clear in their hiring processes about their expectation that former employers’ information should not be used, Ainsworth comments.”